Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.

[1]  G. Bakris,et al.  Differential effects of calcium antagonist subclasses on markers of nephropathy progression. , 2004, Kidney international.

[2]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[3]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[4]  P. Raskin,et al.  Treatment of hypertension in adults with diabetes. , 2003, Diabetes care.

[5]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[6]  G. Viberti,et al.  Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.

[7]  H. von Gizycki,et al.  Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. , 2002, Diabetes care.

[8]  S. Baba,et al.  Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. , 2001, Diabetes research and clinical practice.

[9]  Jan A Staessen,et al.  Cardiovascular protection and blood pressure reduction: a meta-analysis , 2001, The Lancet.

[10]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[11]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[12]  H. Suzuki,et al.  Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[13]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[14]  T. Saruta,et al.  Effect of Combination Therapy of Angiotensin-Converting Enzyme Inhibitor plus Calcium Channel Blocker on Urinary Albumin Excretion in Hypertensive Microalubuminuric Patients with Type II Diabetes , 2000 .

[15]  C. Price,et al.  Performance of a reagent strip device for quantitation of the urine albumin: creatinine ratio in a point of care setting. , 1999, Clinical nephrology.

[16]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[17]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[18]  J. Webster,et al.  A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension. , 1993, British journal of clinical pharmacology.

[19]  F. Cappuccio,et al.  Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. , 1991, Journal of human hypertension.

[20]  P. Dunn,et al.  Urine albumin creatinine ratio and clinical correlates in a diabetic population. , 1987, The New Zealand medical journal.

[21]  E. Lewis,et al.  Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes , 2002 .

[22]  B. Neal.  The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .

[23]  Lui Kf,et al.  Evaluation of a rapid screening test for microalbuminuria with a spot measurement of urine albumin-creatinine ratio. , 2000 .

[24]  S. Fujii.  Potent vasodilative action of cilnidipine on glomerular arterioles in rat hydronephrotic kidney , 1999 .

[25]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.